Citizens has revised its stock price target for MiMedx to $6, citing challenges related to Medicare reimbursement policies. The adjustment reflects concerns over potential headwinds that could impact the company's financial performance. This change in outlook underscores the ongoing scrutiny of the healthcare sector and its implications for companies reliant on Medicare funding.
Related Articles
Don't miss out on breaking stories and in-depth articles.